Diagnosis and comprehensive treatment of pancreatic glucagonoma presenting with multiple metastases and recurring postoperatively
Abstract Background: Pancreatic glucagonoma is a rare neuroendocrine neoplasm with malignant potential. At present, clinicians have a poor understanding of the disease, and the current epidemiology, diagnosis and comprehensive treatment of the disease have not been fully established. Case presentation: Herein, we report two patients with such tumors, one a 60-year-old woman hospitalized for blood glucose elevation and recurrent necrolytic migratory erythema (NME) of the trunk and limbs. Imaging studies showed an area (~3 cm) of reduced enhancement at head of pancreas. Examination of the subsequent pancreaticoduodenectomy specimen confirmed a pancreatic neuroendocrine tumor (G2). The patient’s blood glucose normalized postoperatively, and her skin erythema cleared. During follow-up, however, intramuscular injections (30 mg) of long-acting release (LAR) octreotide acetate microspheres were required at 28-day intervals for recurrent NME, and there was apparent hepatic and retroperitioneal nodal involvement after 36 months. The second patient was a 32-year-old woman hospitalized for recurrent glossitis, perioral dermatitis, and NME of both lower limbs. Imaging studies revealed a low-density nodule (~2 cm) in tail of pancreas, as well as multiple space-occupying lesions of liver. Distal pancreatectomy was undertaken, with splenectomy and palliative resection of hepatic nodules, confirming metastasis of a primary pancreatic neuroendocrine tumor (G2) to liver. The NME resolved postoperatively, but this patient also received intramuscular octreotide LAR injections (30 mg) at 28-day intervals. After 6 months, percutaneous radiofrequency ablation of residual liver lesions took place. Conclusions： In patients with multiple liver metastases, palliative surgical treatment may confer patient benefits and prolong survival. Those with hormonal-based symptoms are often well controlled through somatostatin analog (SSA) administration. postoperative adjuvant therapy of metastatic pancreatic glucagonoma has also obvious effects on the prognosis..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 08. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Shenghui [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2645590/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA038885190 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA038885190 | ||
| 003 | DE-627 | ||
| 005 | 20230409161712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230308s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2645590/v1 |2 doi | |
| 035 | |a (DE-627)XRA038885190 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2645590/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Shenghui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and comprehensive treatment of pancreatic glucagonoma presenting with multiple metastases and recurring postoperatively |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Pancreatic glucagonoma is a rare neuroendocrine neoplasm with malignant potential. At present, clinicians have a poor understanding of the disease, and the current epidemiology, diagnosis and comprehensive treatment of the disease have not been fully established. Case presentation: Herein, we report two patients with such tumors, one a 60-year-old woman hospitalized for blood glucose elevation and recurrent necrolytic migratory erythema (NME) of the trunk and limbs. Imaging studies showed an area (~3 cm) of reduced enhancement at head of pancreas. Examination of the subsequent pancreaticoduodenectomy specimen confirmed a pancreatic neuroendocrine tumor (G2). The patient’s blood glucose normalized postoperatively, and her skin erythema cleared. During follow-up, however, intramuscular injections (30 mg) of long-acting release (LAR) octreotide acetate microspheres were required at 28-day intervals for recurrent NME, and there was apparent hepatic and retroperitioneal nodal involvement after 36 months. The second patient was a 32-year-old woman hospitalized for recurrent glossitis, perioral dermatitis, and NME of both lower limbs. Imaging studies revealed a low-density nodule (~2 cm) in tail of pancreas, as well as multiple space-occupying lesions of liver. Distal pancreatectomy was undertaken, with splenectomy and palliative resection of hepatic nodules, confirming metastasis of a primary pancreatic neuroendocrine tumor (G2) to liver. The NME resolved postoperatively, but this patient also received intramuscular octreotide LAR injections (30 mg) at 28-day intervals. After 6 months, percutaneous radiofrequency ablation of residual liver lesions took place. Conclusions： In patients with multiple liver metastases, palliative surgical treatment may confer patient benefits and prolong survival. Those with hormonal-based symptoms are often well controlled through somatostatin analog (SSA) administration. postoperative adjuvant therapy of metastatic pancreatic glucagonoma has also obvious effects on the prognosis. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Ge, Muxi |4 aut | |
| 700 | 1 | |a Zhang, Cheng |4 aut | |
| 700 | 1 | |a Chen, Lang |4 aut | |
| 700 | 1 | |a Zhao, Lei |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 08. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:08 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2645590/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 08 |c 04 | ||